Health Condition 1: N185- Chronic kidney disease, stage 5
Conditions
Interventions
Intervention1: Desidustat: Desidustat 50mg 2 Tab thrice Weekly for 8 Weeks
Control Intervention1: Recombinant Erythropoietin: Erythropoietin 200IU/kg SC Weekly for 8 Weeks
Sponsors
Faiz Alam
Eligibility
Inclusion criteria
Inclusion criteria: CKD patients with Hemoglobin less than 10 CKD patients not on hemodialysis Only one drug for treating CKD patients with anemia will be studied.
Exclusion criteria
Exclusion criteria: CKD patients on hemodialysis CKD patients having hemoglobin more than 10. Primary anemia Anemia secondary to blood loss Anemia secondary to infectious disease Anemia secondary to malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To study the efficacy and safety of HIF prolyl hydroxylase inhibitor as compared to erythropoetin in anemia with CKD patients not on dialysis. 2. To study the increase in risk of cardiovascular events in patients on desidustat therapy compared to erythropoetin. 3 To study the change in hemoglobin in patients on desidustat therapy compared to epoetin as primary outcome.Timepoint: At Baseline and at 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To study the change in iron related parameters ( TIBC, Hepcidin , Ferritin , serum iron, Transferrin, Tsat) . 2.Occurence of each adverse effectsTimepoint: At baseline at & at 8 weeks | — |
Countries
India
Contacts
Public ContactFaiz Alam
Department of medicine Jawaharlal Nehru medical college aligarh
Outcome results
None listed